These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31694063)

  • 1. ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
    Gundabolu K; Goldsweig A; Bhatt VR; Koepsell SA; Harper JL
    Haemophilia; 2020 Jan; 26(1):e5-e8. PubMed ID: 31694063
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
    Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
    Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review.
    Villarreal-Martínez L; Sepúlveda-Orozco MDC; García-Viera DA; Robles-Sáenz DA; Bautista-Gómez AJ; Ortiz-Castillo M; González-Martínez G; Mares-Gil JE
    Blood Coagul Fibrinolysis; 2021 Sep; 32(6):418-422. PubMed ID: 33859115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor.
    Chen YW; Chen WJ; Tseng MS; Lo HC; Shih MY; Chen YJ; Lee WL; Wang JD
    Haemophilia; 2021 May; 27(3):e385-e388. PubMed ID: 32997880
    [No Abstract]   [Full Text] [Related]  

  • 5. Emicizumab for the treatment of haemophilia A: a narrative review.
    Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
    Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab should be prescribed independent of immune tolerance induction.
    Le Quellec S; Negrier C
    Blood Adv; 2018 Oct; 2(20):2783-2786. PubMed ID: 30352952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety first: Tracking adverse events associated with new therapies for people with hemophilia.
    Recht M
    J Thromb Haemost; 2021 Jan; 19 Suppl 1():3-5. PubMed ID: 33331044
    [No Abstract]   [Full Text] [Related]  

  • 10. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.
    Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF
    Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028
    [No Abstract]   [Full Text] [Related]  

  • 11. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
    Dargaud Y; Lienhart A; Janbain M; Le Quellec S; Enjolras N; Negrier C
    Haematologica; 2018 Apr; 103(4):e181-e183. PubMed ID: 29472355
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 14. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab.
    Garcia J; Zia A
    Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 17. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do we need all that emicizumab?
    Lehtinen AE; Lassila R
    Haemophilia; 2022 Mar; 28(2):e53-e55. PubMed ID: 34970820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.